Intravitreal Bevacizumab for Treatment of Macular Edema Secondary to Hemicentral Retinal Venous Occlusion and Concentrations of Cytokine in Aqueous Humor
Journal of the Korean Ophthalmological Society
; : 293-298, 2011.
Article
de Ko
| WPRIM
| ID: wpr-30464
Bibliothèque responsable:
WPRO
ABSTRACT
PURPOSE: To evaluate the effects of intravitreal bevacizumab and to investigate the concentrations of cytokine in the aqueous humors of patients with macular edema secondary to hemicentral retinal venous occlusion. METHODS: Fifteen eyes of 15 patients with macular edema secondary to hemicentral retinal venous occlusion received intravitreal bevacizumab injections and completed 12 months of follow-up. Cytokine levels were measured in the aqueous humors of these patients using a multiplex bead assay and the levels were compared with those of the controls. RESULTS: During 12 months of follow-up, a mean of 4.5 intravitreal bevacizumab injections were performed. The visual acuity and the central macular thickness improved significantly (p = 0.028, p = 0.000) after treatment. The levels of interleukin-6, vascular endothelial growth factor, and monocyte chemoattractant protein-1 were increased in the aqueous humor compared with the levels in the control group (p = 0.010, p = 0.045, p < 0.001). CONCLUSIONS: Elevated cytokine levels were identified in the aqueous humor after hemicentral retinal venous occlusion. Intravitreal bevacizumab injections were effective for improvements in visual acuity and macular edema due to hemicentral retinal venous occlusion.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Humeur aqueuse
/
Rétinal
/
Acuité visuelle
/
Oedème maculaire
/
Études de suivi
/
Interleukine-6
/
Chimiokine CCL2
/
Facteur de croissance endothéliale vasculaire de type A
/
Oeil
/
Anticorps monoclonaux humanisés
Type d'étude:
Observational_studies
/
Prognostic_studies
Limites du sujet:
Humans
langue:
Ko
Texte intégral:
Journal of the Korean Ophthalmological Society
Année:
2011
Type:
Article